Larimar Therapeutics, Inc. Stock price

Equities

LRMR

US5171251003

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
7.59 USD +4.47% Intraday chart for Larimar Therapeutics, Inc. -11.02% +66.81%
Sales 2024 * - Sales 2025 * - Capitalization 464M
Net income 2024 * -78M Net income 2025 * -140M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-6 x
P/E ratio 2025 *
-3.74 x
Employees 42
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.66%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Larimar Therapeutics, Inc.

1 day+0.90%
1 week-14.83%
Current month-36.83%
1 month-38.12%
3 months+54.25%
6 months+61.80%
Current year+59.67%
More quotes
1 week
7.08
Extreme 7.08
8.64
1 month
7.08
Extreme 7.08
11.97
Current year
4.09
Extreme 4.09
13.68
1 year
2.18
Extreme 2.18
13.68
3 years
1.53
Extreme 1.53
17.25
5 years
1.53
Extreme 1.53
25.87
10 years
1.53
Extreme 1.53
25.87
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 -
Director of Finance/CFO 65 20-05-27
Chief Tech/Sci/R&D Officer - 18-04-30
Members of the board TitleAgeSince
Director/Board Member 55 20-05-27
Director/Board Member 54 20-05-27
Director/Board Member 69 23-10-02
More insiders
Date Price Change Volume
24-03-28 7.59 +4.47% 514 809
24-03-27 7.265 +0.90% 442,161
24-03-26 7.2 -5.01% 522,207
24-03-25 7.58 -6.30% 514,406
24-03-22 8.09 -5.49% 781,587

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases using its cell penetrating peptide (CPP) technology platform. The Company's lead compound, CTI-1601, is being developed as a potential treatment for Friedreichs ataxia (FA). CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with FA. FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient frataxin (FXN) due to a genetic abnormality.It also focuses on using its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. Its CPP platform enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.265 USD
Average target price
18.84 USD
Spread / Average Target
+159.30%
Consensus
  1. Stock
  2. Equities
  3. Stock Larimar Therapeutics, Inc. - Nasdaq